GLP-1 and Pregnancy or Breastfeeding: What the Labels Actually Say

This is one of the most commonly garbled facts about GLP-1 medications, and getting it wrong matters. Some coverage treats "GLP-1s and breastfeeding" as one blanket rule across every product. It isn't. The actual language differs by formulation and by molecule, and the difference is specific enough that it's worth reading the labels directly rather than a summary. Here's what the current FDA-approved prescribing information for Wegovy, Ozempic, Mounjaro, and Zepbound actually says.

The breastfeeding language is not the same across formulations

Wegovy now comes in two forms approved under the same label: an injection and an oral tablet. They are not treated identically on breastfeeding. The tablet carries an explicit advisory: prescribers are instructed to "advise patients that breastfeeding is not recommended during treatment with WEGOVY tablets"¹. The injection uses a clinical benefit-risk assessment and notes a lack of human milk data; that does not establish safety during breastfeeding¹.

Ozempic — semaglutide injection, approved for type 2 diabetes rather than weight management — uses standard risk-benefit language instead of a restriction: prescribers are told "the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for OZEMPIC and any potential adverse effects on the breastfed infant"². That advice refers to Ozempic injection. Novo’s current safety information also says breastfeeding is not recommended with Ozempic tablets⁵. Do not transfer injection advice to a tablet.

Tirzepatide's two brands — Mounjaro (diabetes) and Zepbound (weight management) — go a step further in the other direction. Both labels report that tirzepatide concentration in breast milk was "either undetectable or low" compared with the maternal dose, with Zepbound's label specifying less than 0.02% of the maternal dose detected, but neither study established effects on the infant or milk production. The labels require weighing breastfeeding benefits, clinical need and potential infant harm³⁴.

The takeaway on breastfeeding

If you see a claim that "GLP-1 injections are contraindicated during breastfeeding," that's imprecise. Wegovy and Ozempic tablets carry advice against breastfeeding during treatment¹⁵. The injectable semaglutide and tirzepatide products use standard clinical judgment language, not a blanket "do not use" instruction. This distinction matters enough that it's worth confirming with your own prescriber which formulation you'd actually be prescribed, since telehealth programs vary in which one they offer — see how programs differ on this in our provider reviews.

The pre-conception washout window

Separately from breastfeeding, both Wegovy formulations and Ozempic carry explicit guidance to stop before trying to conceive. The Wegovy label instructs discontinuing "at least 2 months before" a planned pregnancy, to account for the drug's long elimination half-life¹. Ozempic's label uses nearly identical language: "Discontinue OZEMPIC in women at least 2 months before a planned pregnancy due to the long washout period for semaglutide"². For weight-reduction use specifically, the Wegovy label also instructs discontinuing use once pregnancy is confirmed¹.

The Mounjaro and Zepbound labels we reviewed do not include an equivalent explicit pre-conception washout window the way the semaglutide labels do — Zepbound instructs stopping when pregnancy is recognized, while Mounjaro says use in pregnancy should occur only when the potential benefit justifies fetal risk³⁴. If pregnancy planning is part of your timeline, this is a difference worth raising directly with your prescriber rather than assuming the semaglutide rule applies across every product.

Tirzepatide and oral contraception

Mounjaro and Zepbound can reduce the effectiveness of oral hormonal contraceptives. Their labels advise switching to non-oral contraception or adding a barrier method for four weeks after starting treatment and four weeks after each dose increase³⁴. Discuss a pregnancy-prevention and treatment plan with your clinician.

Why the data gaps exist in the first place

None of this precision changes the underlying reality: pregnant and breastfeeding people are rarely enrolled in the placebo-controlled trials that generate a drug's core safety data, for the same ethical reasons across nearly all new medications. That's why you'll see language like "no human milk data are available" for the Wegovy injection rather than a definitive finding either way¹ — it's an honest description of a data gap, not a hidden red flag. The Mounjaro and Zepbound reports of "undetectable or low" breast milk concentrations come from smaller, targeted lactation studies rather than the large randomized trials that generated the weight-loss and side-effect numbers covered in GLP-1 side effects: what the STEP and SURMOUNT trials actually reported³⁴. Knowing the difference between "we checked and it's low" and "we haven't been able to check" is part of reading a label accurately instead of over- or under-interpreting it. It also explains why label language changes over time as more data accumulates — a formulation's pregnancy and lactation section isn't fixed forever, which is one more reason to check the current version rather than relying on something you read a year or two ago.

Why this level of precision matters

Fast-moving areas of drug labeling are exactly where secondhand summaries go stale or get flattened into an oversimplified rule. If you're planning a pregnancy, breastfeeding, or simply want an accurate answer, the source that matters is the current label for the specific product you'd actually be prescribed — not a general "GLP-1s and pregnancy" headline. This is also relevant if you're weighing whether to stop treatment for other reasons; see what happens when you stop GLP-1 medication for the weight-regain evidence that applies regardless of why you pause.

If PCOS is part of why you're considering a GLP-1 in the first place

For some people, the path to this page starts earlier — using a GLP-1 partly to address PCOS-related weight and hormonal symptoms with an eye toward improving fertility odds. If that's your situation, see GLP-1 and PCOS: what the fertility evidence shows for what the randomized trial data actually supports, and plan the pre-conception washout window covered above into that timeline rather than treating it as a separate, later decision.

Talk to your prescriber before you plan around this

Nothing here is a substitute for a conversation with the clinician managing your care, especially if pregnancy is a near-term possibility. A program with a real medical intake — not just a checkout flow — should be the one walking you through this, while our Value Score methodology separately compares pricing and program terms. Compare programs by price on our semaglutide and tirzepatide rankings once you've confirmed the medical process behind the sticker is a real one.

This piece sits in our research index alongside every other sourced explainer we publish — the trials, the compounding rules and the pricing mechanics, grouped by the question each one answers.